Creative Planning’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.92M Sell
52,228
-2,546
-5% -$201K ﹤0.01% 1376
2025
Q4
$4.33M Buy
54,774
+3,300
+6% +$248K ﹤0.01% 1108
2025
Q3
$3.37M Sell
51,474
-1,815
-3% -$88.6K ﹤0.01% 1133
2025
Q2
$2.11M Buy
53,289
+17,167
+48% +$562K ﹤0.01% 1274
2025
Q1
$1.09M Sell
36,122
-10,681
-23% -$350K ﹤0.01% 1652
2024
Q4
$1.64M Buy
46,803
+18,421
+65% +$689K ﹤0.01% 1267
2024
Q3
$1.14M Buy
28,382
+1,522
+6% +$70.8K ﹤0.01% 1423
2024
Q2
$1.28M Sell
26,860
-145
-0.5% -$5.95K ﹤0.01% 1244
2024
Q1
$1.17M Buy
27,005
+1,706
+7% +$81.3K ﹤0.01% 1232
2023
Q4
$1.28M Buy
25,299
+3,727
+17% +$179K ﹤0.01% 1110
2023
Q3
$979K Buy
21,572
+6,329
+42% +$261K ﹤0.01% 1170
2023
Q2
$625K Buy
15,243
+1,611
+12% +$61.9K ﹤0.01% 1416
2023
Q1
$487K Buy
13,632
+204
+2% +$7.66K ﹤0.01% 1485
2022
Q4
$507K Sell
13,428
-464
-3% -$19.5K ﹤0.01% 1416
2022
Q3
$614K Buy
13,892
+1,163
+9% +$49K ﹤0.01% 1202
2022
Q2
$471K Sell
12,729
-29
-0.2% -$1.09K ﹤0.01% 1356
2022
Q1
$472K Sell
12,758
-2,358
-16% -$77.2K ﹤0.01% 1351
2021
Q4
$460K Buy
15,116
+201
+1% +$6.33K ﹤0.01% 1356
2021
Q3
$500K Buy
14,915
+1,595
+12% +$60.1K ﹤0.01% 1291
2021
Q2
$531K Sell
13,320
-30,859
-70% -$1.21M ﹤0.01% 1245
2021
Q1
$1.99M Buy
44,179
+8,739
+25% +$487K ﹤0.01% 729
2020
Q4
$2M Sell
35,440
-47
-0.1% -$2.34K ﹤0.01% 674
2020
Q3
$1.68M Buy
35,487
+16,201
+84% +$900K ﹤0.01% 619
2020
Q2
$1.14M Buy
19,286
+40
+0.2% +$2.23K ﹤0.01% 703
2020
Q1
$910K Sell
19,246
-1,805
-9% -$101K ﹤0.01% 686
2019
Q4
$1.27M Sell
21,051
-2,234
-10% -$133K ﹤0.01% 679
2019
Q3
$1.4M Buy
23,285
+552
+2% +$36K ﹤0.01% 619
2019
Q2
$1.46M Buy
22,733
+106
+0.5% +$7.49K ﹤0.01% 603
2019
Q1
$1.84M Sell
22,627
-4,808
-18% -$310K 0.01% 494
2018
Q4
$1.48M Buy
27,435
+817
+3% +$41.7K 0.01% 508
2018
Q3
$1.37M Buy
26,618
+2,320
+10% +$109K 0.01% 618
2018
Q2
$1.01M Buy
24,298
+611
+3% +$27.1K ﹤0.01% 743
2018
Q1
$1.04M Sell
23,687
-1,679
-7% -$85.3K ﹤0.01% 716
2017
Q4
$1.28M Sell
25,366
-137
-0.5% -$7.51K 0.01% 602
2017
Q3
$1.29M Sell
25,503
-996
-4% -$52.2K 0.01% 601
2017
Q2
$1.35M Sell
26,499
-357
-1% -$16.6K 0.01% 565
2017
Q1
$1.08M Buy
26,856
+1,442
+6% +$64.8K 0.01% 637
2016
Q4
$1.22M Sell
25,414
-801
-3% -$31.7K 0.01% 558
2016
Q3
$961K Sell
26,215
-252
-1% -$7.88K 0.01% 610
2016
Q2
$616K Buy
26,467
+5,991
+29% +$193K ﹤0.01% 688
2016
Q1
$829K Sell
20,476
-2,217
-10% -$90K 0.01% 556
2015
Q4
$1.41M Buy
22,693
+989
+5% +$53.4K 0.01% 402
2015
Q3
$877K Buy
21,704
+3,018
+16% +$156K 0.01% 515
2015
Q2
$1.07M Buy
18,686
+6,982
+60% +$444K 0.01% 447
2015
Q1
$745K Sell
11,704
-8,050
-41% -$546K 0.01% 568
2014
Q4
$1.22M Buy
19,754
+10,492
+113% +$518K 0.01% 391
2014
Q3
$360K Sell
9,262
-11,396
-55% -$404K ﹤0.01% 785
2014
Q2
$712K Buy
20,658
+14,790
+252% +$466K 0.01% 509
2014
Q1
$254K Buy
5,868
+248
+4% +$12K ﹤0.01% 888
2013
Q4
$224K Buy
5,620
+3,467
+161% +$124K ﹤0.01% 816
2013
Q3
$81K Buy
2,153
+1,500
+230% +$44.8K ﹤0.01% 1244
2013
Q2
$18K Buy
+653
New +$13.9K ﹤0.01% 1996

Other funds holding IONS

Creative Planning's IONS Position: Q1 2026 in Review

Creative Planning reduced its Ionis Pharmaceuticals (IONS) stake by 4.6% in Q1 2026, selling an estimated $201K and leaving 52,228 shares worth $3.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Creative Planning first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.33M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Creative Planning held 52,228 shares of Ionis Pharmaceuticals worth $3.92M as of Q1 2026.
  • Creative Planning sold 2,546 Ionis Pharmaceuticals shares in Q1 2026, an estimated $201K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1376 holding.
  • Creative Planning first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Creative Planning's Ionis Pharmaceuticals position peaked at $4.33M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.